{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T10:13:23Z","timestamp":1778753603082,"version":"3.51.4"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Youth Project of Guangdong Provincial Medical Science and Technology Research Fund","award":["A2022378"],"award-info":[{"award-number":["A2022378"]}]},{"DOI":"10.13039\/501100012151","name":"Sanming Project of Medicine in Shenzhen","doi-asserted-by":"crossref","award":["SZSM202411015"],"award-info":[{"award-number":["SZSM202411015"]}],"id":[{"id":"10.13039\/501100012151","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-06747-1","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T07:50:54Z","timestamp":1777449054000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Anti-CD19 chimeric antigen receptor (CAR)-T cell therapy vs. CD20xCD3 bispecific antibody as third- or later-line treatment in follicular lymphoma: a meta-analysis"],"prefix":"10.1007","volume":"105","author":[{"given":"Xueying","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiehao","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaocong","family":"Mo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"issue":"9","key":"6747_CR1","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1002\/ajh.24086","volume":"90","author":"M Al-Hamadani","year":"2015","unstructured":"Al-Hamadani M et al (2015) Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: A longitudinal analysis of the National cancer data base from 1998 to 2011. Am J Hematol 90(9):790\u2013795","journal-title":"Am J Hematol"},{"issue":"7","key":"6747_CR2","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1200\/JCO.2017.74.1652","volume":"36","author":"S Luminari","year":"2018","unstructured":"Luminari S et al (2018) Long-Term results of the FOLL05 trial comparing R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with Advanced-Stage symptomatic follicular lymphoma. J Clin Oncol 36(7):689\u2013696","journal-title":"J Clin Oncol"},{"issue":"19","key":"6747_CR3","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","volume":"123","author":"IW Flinn","year":"2014","unstructured":"Flinn IW et al (2014) Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood 123(19):2944\u20132952","journal-title":"Blood"},{"issue":"14","key":"6747_CR4","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","volume":"377","author":"R Marcus","year":"2017","unstructured":"Marcus R et al (2017) Obinutuzumab for the First-Line treatment of follicular lymphoma. N Engl J Med 377(14):1331\u20131344","journal-title":"N Engl J Med"},{"issue":"23","key":"6747_CR5","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","volume":"33","author":"C Casulo","year":"2015","unstructured":"Casulo C et al (2015) Early relapse of follicular lymphoma after rituximab plus Cyclophosphamide, Doxorubicin, Vincristine, and prednisone defines patients at high risk for death: an analysis from the National lymphocare study. J Clin Oncol 33(23):2516\u20132522","journal-title":"J Clin Oncol"},{"issue":"17","key":"6747_CR6","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1182\/blood.2023021567","volume":"143","author":"M Dreyling","year":"2024","unstructured":"Dreyling M et al (2024) Durable response after tisagenlecleucel in adults with relapsed\/refractory follicular lymphoma: ELARA trial update. Blood 143(17):1713\u20131725","journal-title":"Blood"},{"issue":"8","key":"6747_CR7","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1038\/s41591-024-02986-9","volume":"30","author":"F Morschhauser","year":"2024","unstructured":"Morschhauser F et al (2024) Lisocabtagene Maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study. Nat Med 30(8):2199\u20132207","journal-title":"Nat Med"},{"issue":"6","key":"6747_CR8","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1182\/blood.2023021243","volume":"143","author":"SS Neelapu","year":"2024","unstructured":"Neelapu SS et al (2024) Three-year follow-up analysis of Axicabtagene Ciloleucel in relapsed\/refractory indolent non-Hodgkin lymphoma (ZUMA-5). Blood 143(6):496\u2013506","journal-title":"Blood"},{"issue":"8","key":"6747_CR9","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","volume":"23","author":"LE Budde","year":"2022","unstructured":"Budde LE et al (2022) Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. Lancet Oncol 23(8):1055\u20131065","journal-title":"Lancet Oncol"},{"issue":"8","key":"6747_CR10","doi-asserted-by":"publisher","first-page":"e593","DOI":"10.1016\/S2352-3026(24)00166-2","volume":"11","author":"KM Linton","year":"2024","unstructured":"Linton KM et al (2024) Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study. Lancet Haematol 11(8):e593\u2013e605","journal-title":"Lancet Haematol"},{"issue":"11","key":"6747_CR11","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/j.annonc.2024.08.2239","volume":"35","author":"TM Kim","year":"2024","unstructured":"Kim TM et al (2024) Safety and efficacy of Odronextamab in patients with relapsed or refractory follicular lymphoma. Ann Oncol 35(11):1039\u20131047","journal-title":"Ann Oncol"},{"issue":"6","key":"6747_CR12","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1182\/blood.2023023419","volume":"144","author":"J Kim","year":"2024","unstructured":"Kim J et al (2024) CAR T cells vs bispecific antibody as third- or later-line large B-cell lymphoma therapy: a meta-analysis. Blood 144(6):629\u2013638","journal-title":"Blood"},{"issue":"7","key":"6747_CR13","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1182\/blood.2024025454","volume":"145","author":"LH Sehn","year":"2025","unstructured":"Sehn LH et al (2025) Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after >\/=2 prior therapies. Blood 145(7):708\u2013719","journal-title":"Blood"},{"issue":"2","key":"6747_CR14","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s10147-024-02662-5","volume":"30","author":"H Goto","year":"2025","unstructured":"Goto H et al (2025) Efficacy and safety of mosunetuzumab monotherapy for Japanese patients with relapsed\/refractory follicular lymphoma: FLMOON-1. Int J Clin Oncol 30(2):389\u2013396","journal-title":"Int J Clin Oncol"},{"issue":"5","key":"6747_CR15","doi-asserted-by":"publisher","first-page":"e327","DOI":"10.1016\/S2352-3026(22)00072-2","volume":"9","author":"R Bannerji","year":"2022","unstructured":"Bannerji R et al (2022) Odronextamab, a human CD20xCD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet Haematol 9(5):e327\u2013e339","journal-title":"Lancet Haematol"},{"issue":"1","key":"6747_CR16","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s40164-025-00610-1","volume":"14","author":"LJ Nastoupil","year":"2025","unstructured":"Nastoupil LJ et al (2025) Matching-adjusted indirect comparison of efficacy and safety of lisocabtagene Maraleucel and mosunetuzumab for the treatment of third-line or later relapsed or refractory follicular lymphoma. Exp Hematol Oncol 14(1):30","journal-title":"Exp Hematol Oncol"},{"key":"6747_CR17","doi-asserted-by":"publisher","first-page":"927153","DOI":"10.3389\/fimmu.2022.927153","volume":"13","author":"X Zhang","year":"2022","unstructured":"Zhang X et al (2022) CAR-T cell therapy in hematological malignancies: current opportunities and challenges. Front Immunol 13:927153","journal-title":"Front Immunol"},{"key":"6747_CR18","doi-asserted-by":"crossref","unstructured":"Benmebarek MR et al (2019) Killing mechanisms of chimeric antigen receptor (CAR) T cells. Int J Mol Sci, 20(6):1283","DOI":"10.3390\/ijms20061283"},{"key":"6747_CR19","doi-asserted-by":"crossref","unstructured":"Sun L, Romancik JT (2025) The development and application of bispecific antibodies in B-Cell Non-Hodgkin lymphoma. J Pers Med, 15(2):51","DOI":"10.3390\/jpm15020051"},{"issue":"26","key":"6747_CR20","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","volume":"127","author":"JN Brudno","year":"2016","unstructured":"Brudno JN, Kochenderfer JN (2016) Toxicities of chimeric antigen receptor T cells: recognition and management. Blood 127(26):3321\u20133330","journal-title":"Blood"},{"issue":"10396","key":"6747_CR21","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/S0140-6736(23)00521-4","volume":"402","author":"N van de Donk","year":"2023","unstructured":"van de Donk N, Zweegman S (2023) T-cell-engaging bispecific antibodies in cancer. Lancet 402(10396):142\u2013158","journal-title":"Lancet"},{"key":"6747_CR22","doi-asserted-by":"crossref","unstructured":"Yan S et al (2025) Neurological complications associated with chimeric antigen receptor T cell therapy. J Cereb Blood Flow Metab","DOI":"10.1177\/0271678X251332492"},{"key":"6747_CR23","doi-asserted-by":"crossref","unstructured":"Bayly-McCredie E, Treisman M, Fiorenza S (2024) Safety and efficacy of bispecific antibodies in adults with large B-Cell lymphomas: A systematic review of clinical trial data. Int J Mol Sci, 25(17):9736","DOI":"10.3390\/ijms25179736"},{"issue":"13","key":"6747_CR24","doi-asserted-by":"publisher","first-page":"3555","DOI":"10.1182\/bloodadvances.2024012916","volume":"8","author":"GK Reynolds","year":"2024","unstructured":"Reynolds GK et al (2024) Infections in patients with lymphoma treated with bispecific antibodies: a systematic review and meta-analysis. Blood Adv 8(13):3555\u20133559","journal-title":"Blood Adv"},{"issue":"10","key":"6747_CR25","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1182\/blood.2022015956","volume":"140","author":"N Philipp","year":"2022","unstructured":"Philipp N et al (2022) T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals. Blood 140(10):1104\u20131118","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06747-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06747-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06747-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T09:22:01Z","timestamp":1778750521000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06747-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":25,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["6747"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06747-1","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,29]]},"assertion":[{"value":"28 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics and consent to participate declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"274"}}